Humoral immune response against p53 protein in patients with colorectal carcinoma

International Journal of Cancer

Volumn 70, Issue 1, 1997, Pages 46-51

  Angelopoulou, Katerina ^a   Stratis, Michael ^b   Diamandis, Eleftherios P ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; PROTEIN P53; PROTEIN P53 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; ANTIBODY FORMATION; BLOTTING, WESTERN; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECTAL NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031033120     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970106)70:1<46::AID-IJC7>3.0.CO;2-6     Document Type: Article

References (19)

1. ANGELOPOULOU, K. and DIAMANDIS, E.P., Quantification of antibodies against the p53 tumor suppressor gene product in the serum of cancer patients. Cancer J., 6, 315-321 (1993).
2. ANGELOPOULOU, K., DIAMANDIS, E.P., SUTHERLAND, D.J.A., KELLEN, J.A. and BUNTING, P.S., Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer, 58, 480-487 (1994).
3. BAKER, S.J., MARKOWITZ, S., FEARON, E.R., WILSON, J.K.U. and VOGELSTEIN, B., Suppression of human colorectal carcinoma cell growth by wild-type p53. Science, 249, 912-915 (1990).
4. CARON DE FROMENTEL, C., MAY-LEVINE, F., MOURIESSE, H., LEMERLE, J., CHANDRASEKARAN, K. and MAY, P., Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int. J. Cancer, 39, 185-189 (1987).
5. CARON DE FROMENTEL, C. and SOUSSI, T., TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer, 4, 1-15 (1992).
6. CHRISTOPOULOS, T.K. and DIAMANDIS, E.P., Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal. Chem., 64, 342-346 (1992).
7. CRAWFORD, L.V., PIW, D.C. and BULBROOK, R.D., Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer, 30, 403-408 (1982).
8. DAVIDOFF, A.M., IGLEHART, J.D. and MARKS, J.R., Immune response to p53 is dependent upon p53 HSP70 complexes in breast cancers. Proc. nat. Acad. Sci. (Wash.), 89, 3439-3442 (1992).
9. FINLAY, C.A., HINDS, P.W. and LEVINE, A.J., The p53 protooncogene can act as a suppressor of transformation. Cell, 57, 1083-1093 (1989).
10. HASSAPOGLIDOU, S., DIAMANDIS, E.P. and SUTHERLAND, D.J.A., Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. Oncogene, 8, 1501-1509 (1993).
11. HOLLSTEIN, M., SIDRANSKY, D., VOGELSTEIN, B. and HARRIS, C.C., p53 mutations in human cancers. Science, 253, 49-53 (1991).
12. LUBIN, R. and 19 OTHERS, Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res., 53, 5872-5876 (1993).
13. MUDENDA, B., GREEN, J.A., GREEN, B., JENKINS, J.R., ROBERTSON, L., TARUNINA, M. and LEINSTER, S.J., The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Brit. J. Cancer, 69, 1115-1119 (1994).
14. MURAKAMI, Y., HAYASHI, K. and SEKIYA, T., Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res., 51, 3356-3361 (1991).
15. SCHLICHTHOLZ, B., LEGROS, Y., GILLET, D., GAILLARD, C., MARTY, M., LANE, D., CALVO, F. and SOUSSI, T., The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res., 52, 6380-6384 (1992).
16. SCHLICHTHOLZ, B., TREDANIEL, T., LUBIN, R., ZALCMAN, G., HIKSCH, A. and SOUSSI, T., Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Brit. J. Cancer, 69, 809-816 (1994).
17. SOUSSI, T., LEGROS, Y., LUBIN. R., ORY, K. and SCHLICHTHOLZ, B., Multifactorial analysis of p53 alteration in human cancer: a review. Int. J. Cancer, 57, 1-9 (1994).
18. VOJTESEK, B., BARTEK, J., MIDGLEY, C.A. and LANE, D.P., An immunohistochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. immunol. Methods, 151, 237-244 (1992).
19. WINTER, S.F., MINNA, J.D., JOHNSON, B.E., TAKAHASHI, T., GAZDAR, A.F. and CARBONE, D.P., Development of antibodies against p53 in lung cancer patients appears to be dependent on the p53 mutation. Cancer Res., 52, 4168-4174 (1992).